Additionally, no analyses on the effective dose of Klotho or the needed frequency of its administration were performed, which must be done before introducing Klotho as a promising agent in immunotherapy for diabetes and diabetic nephropathy. This evidence concerns the gene KL and diabetic kidney disease.